Bharat Biotech's Covaxin found 81% effective in interim phase 3 trials3 min read . Updated: 03 Mar 2021, 05:12 PM IST
- 'Covaxin demonstrates high clinical efficacy trend against COVID-19 but also significant immunogenicity against the rapidly emerging variants,' said Chairman and Managing Director Krishna Ella
- The clinical trial will continue through to final analysis at 130 confirmed cases in order to gather further data and to evaluate the efficacy of Covaxin in additional secondary study endpoints
Hyderabad-based vaccine manufacturing company Bharat Biotech on Wednesday announced phase 3 clinical results of its indigenously-made Covid-19 vaccine candidate, Covaxin. In the trial results, the company says that Covaxin demonstrates an interim clinical efficacy of 81% against novel coronavirus.
Select your Category